A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
Clinical trial NCT05594381 · UNKNOWN
Trial details
- NCT number
- NCT05594381
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2023-09-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.